US Pharma MarketingUCB bets $2B on Candid's T cell engager ambitions
UCB is paying $2 billion upfront to acquire Candid Therapeutics, the companies said Sunday afternoon. The Belgian pharma could pay up to another $200 million down the road if the San Diego and Shanghai biotech hits certain milestones. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the…
Ken Song has done it again.
The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies.
UCB is paying $2 ...
Source: Endpoints News